Inovio to Ship VOCERYQ Within 60 Days After FDA Accelerated Approval
FDA granted accelerated approval to VOCERYQ on October 30. Inovio ships within 60 days, targets payer coverage of 80% of the ~25,000 US RRP patients within nine months.
TAG C-1418 · 580 words on the filing

Summary of findings
- FDA granted accelerated approval to VOCERYQ on October 30; first shipments expected within 60 days.
- 72% of Phase 1/2 patients cut surgeries by at least 50% in year one; 28% needed no surgery.
- Inovio targets payer policies covering 80% of ~25,000 US RRP patients within nine months of approval.
- Cash funds operations through Q4 next year; the company reports no debt.
- A conditional marketing authorization application is filed with the EMA.
Inovio Pharmaceuticals expects to ship VOCERYQ within 60 days of its October 30 FDA accelerated approval, launching the company's first approved product into a US recurrent respiratory papillomatosis (RRP) market it sizes at roughly 25,000 active patients. President and CEO Jacqueline Shea said the full field force, deployed with Syneos Health, will be in place in the first quarter of next year.
The FDA granted accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with RRP, a rare disease in which human papillomavirus drives wart-like growths in the respiratory tract. Shea said repeated surgery has been the standard of care, but procedures can damage the vocal cords and affect patients' ability to speak.
What is the product and the regimen?
VOCERYQ is regulated as a combination product: two DNA plasmids administered with Inovio's CELLECTRA 5PSP delivery device. One plasmid encodes antigens from the HPV types that cause RRP; the other encodes human IL-12, an immune adjuvant intended to enhance the response. The regimen consists of four doses over nine weeks.
What did the trial data show?
In a Phase 1/2 trial, patients had undergone at least two surgeries in the year before treatment. The study required no additional surgeries during the dosing window; surgeries after treatment counted toward the efficacy endpoint. Shea reported:
- 72% of patients achieved a reduction of at least 50% in surgeries in the first year versus the pre-treatment year.
- 28% required no surgery at all in year one.
- In retrospective follow-up, 86% sustained a reduction of at least 50% in the second year, and 50% required no surgery.
- For the accelerated approval analysis, the FDA evaluated patients with at least three surgeries in the prior year; among that group, 27% needed no surgeries in the 12 months after completing treatment.
Shea described the safety profile as well tolerated, with a low rate of systemic adverse events.
How will the launch be executed?
The commercial footprint is deliberately narrow. About 400 US laryngologists treat the vast majority of RRP patients, and Inovio's planned field force should cover approximately 90% of the patient opportunity. On access, the company aims to have payer policies covering 80% of patients within nine months of approval.
Shea said most patients are still managed surgically and only a fraction have received immunotherapy. She positioned VOCERYQ as a potential preferred first-line immunotherapy, citing its dosing regimen, tolerability and the potential for administration in a physician's office. She also noted that another immunotherapy has recently been approved for RRP, giving the class its first direct competition.
What comes next for the pipeline and the balance sheet?
Inovio plans to explore continued VOCERYQ treatment, pediatric use and expansion into additional geographic markets. The company has submitted a conditional marketing authorization application to the European Medicines Agency.
Beyond VOCERYQ, the pipeline includes INO-3112 for HPV-positive head and neck cancer and INO-5412 for glioblastoma. Inovio is also seeking partners for preclinical programs in hemophilia A, Fabry disease and hypophosphatasia.
On funding: Shea said current cash and equivalents would finance operations through the end of the fourth quarter of next year without additional fundraising or revenue, and the company carries no debt on its balance sheet.
For a DNA-medicine developer shipping its first commercial product on a two-person-molecule combination platform, the next two quarters will test whether a 400-physician target list can carry a launch without new capital.
via FDA industry wire (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
22 articles
Linked filings
- V-5532
- P-6323
- K-4995
- K-7275
- T-8353